THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) PRESENTS

Three Outstanding Training Opportunities
Supported by Major Grants from the National Cancer Institute
Primarily for Postdoctoral and Oncology Fellows

Waiver of Registration Fees and Subsidy of Lodging and Subsistence Expenses for Qualified Fellows

Molecular Biology in Clinical Oncology
A thorough overview of concepts in molecular biology designed for clinical oncologists in training

July 3-9, 1998, The Given Biomedical Institute, Aspen, CO
Michael B. Kastan, L. Michael Glodé, and Jennifer A. Pietenpol, Organizers

• Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology
• Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology
• Career development session and scheduled networking opportunities

Molecular Biology and Pathology of Neoplasia
(formerly entitled Histopathobiology of Neoplasia)
The Edward A. Smuckler Memorial Workshop
Intensive training in the molecular biology and morphology of human cancer for graduate students and postdoctoral fellows contemplating careers in basic cancer research

Frederick M. Waldman, Course Director

• Twenty-eight hours of hands-on laboratory exercises directed by distinguished pathologists
• An outstanding series of lectures on rapidly developing areas of cancer research by laboratory directors and other prominent investigators
• Poster presentations by students and faculty to facilitate further scientific exchange

Methods in Clinical Cancer Research
Co-Sponsored by the American Society of Clinical Oncology (ASCO)
The essentials of clinical trials design for researchers at the level of fellow or junior faculty

Daniel D. Von Hoff and Charles A. Coltman, Jr., Chairpersons

• A series of lectures by leaders in the field covering all elements of clinical trials design
• Small group discussion sessions on important techniques in clinical research
• Development of a clinical trial protocol by all participants with detailed critiques by faculty members
• Category I CME credits through ASCO

AACR members will receive brochures for all three workshops as soon as they are available. (The Clinical Methods Workshop brochure is also mailed to all ASCO members.) All others should submit requests to:

American Association for Cancer Research • Public Ledger Building, Suite 826 • 150 S. Independence Mall West
Philadelphia, PA 19106-3483 • Telephone: (215) 440-9300 • FAX: (215) 440-9313 • E-mail: meetings@aacr.org
Website: http://www.aacr.org
International Aspirin® Award 1998

Young Researchers' Aspirin® Award

The Young Researchers' Aspirin® Award's objective is to encourage scientific research into the mechanism of action and clinical use of acetylsalicylic acid, the active ingredient of Aspirin®. Scientists who have contributed to the knowledge of Aspirin® through original independent scientific research in the field of theoretical (experimental) and/or clinical medicine are invited to compete for the Award. The results of their work should have a direct effect on the knowledge or use of Aspirin® and be based on a peer-reviewed publication, accepted and/or published. The publication should not be older than two years. Only 1 paper can be submitted per year but it might be resubmitted within the time limit. The age limit of the Young Researchers' Aspirin® Award in the year of candidature is 40.

The Young Researchers' Aspirin® Award's value is DM 20,000.

Entries will be judged by an international scientific committee representing basic and clinical research.
Submit your manuscript (English language, 2 copies) with your Curriculum Vitae, a list of the 5 most important recent publications (= last 5 years) and a statement of the group leader of the department where the scientific work submitted for the Aspirin® Award competition was generated which describes the background and rationale of the research, confirms the independence of the scientific work and discloses the source of financial funding.

Applications should be mailed to the following address:
International Aspirin® Award
c/o Bayer AG
BG Consumer Care/EU-PDC/Medicine
Building C 151
D-51368 Leverkusen/Germany

Deadline for submission is April 30th, 1998 (postal mark!)
Deputy Director, Division of Clinical Sciences

The Division of Clinical Sciences (DCS) of the National Cancer Institute, National Institutes of Health, conducts research directed toward furthering our understanding of cancer and developing therapies leading to a reduction of the morbidity and mortality of cancer. The Director, DCS, is responsible for providing the scientific leadership and administrative support necessary to advance the clinical and translational research within the Division and Institute.

The Director, DCS, is seeking an outstanding Ph.D. or M.D. senior-level scientist to serve as Deputy Director of Scientific Affairs, DCS. The Deputy Director will be responsible for overseeing the implementation of new scientific programs and initiatives, such as the newly established Advanced Technology Center, and the management of existing programs, such as the DCS Sabbatical Program and Fellowship Programs. The Deputy Director will assist the Director in the development of new translational programs and in the recruitment of key research staff. The Deputy Director will coordinate interdivisional activities and serve as Division contact for intramural and extramural Working Groups. In addition, the Deputy Director will provide administrative oversight for the Division’s personnel and space issues, and work with the Director to determine the optimum program support and/or resource allocation necessary to accomplish Division goals.

The Division is organized into 10 Laboratories/Branches staffed by approximately 1000 individuals composed of personnel positions and fellowship positions, supported with an annual budget of approximately $90 million.

Candidates should be recognized for their research accomplishments and should be experienced in the management of scientific programs. Candidates must possess a medical or other doctoral-level degree in a biomedical or related field. The total annual compensation will be commensurate with education and experience, based on the U.S. Government General Salary Schedule.

All applications should include the following: A letter expressing their interest in the position, a statement of their research interests, curriculum vitae and bibliography, and the names and addresses of five individuals who can be contacted as references. A list of the requirements or additional information about the position may be obtained by contacting Ms. Debbie Breedlove at the address listed below.

Applications should be sent to:

Ms. Debbie Breedlove
Administrative Resource Center 31
National Cancer Institute
National Institutes of Health
Building 31, Room 3A20
31 Center Drive—MSC 2440
Bethesda, Maryland 20892-2440
Telephone: (301) 402-5736
FAX: (301) 480-0215

Selection for this position will be based solely on merit with no discrimination for non-merit reasons such as race, color, gender, national origin, age, religion, sexual orientation, or physical or mental disability.

NIH IS AN EQUAL OPPORTUNITY EMPLOYER
PROTEASES AND THE PROTEASE INHIBITORS IN CANCER
Joint Conference of the
American Association for Cancer Research
and
ACTA Pathologica Microbiologica Immunologica Scandinavia

June 14-18, 1998
Nyborg Strand Hotel
Nyborg, Denmark

CONFERENCE CHAIRPERSONS
Lynn M. Matrisian / Nashville, USA
Keld Danø / Copenhagen, Denmark

SCIENTIFIC PROGRAM

Keynote Lectures
*Alan Barrett / Cambridgeshire, England
Wolfram Bode / Martinsried, Germany
Zena Werb / San Francisco, USA

Molecular Mechanisms Regulating Protease Activity
*Karl Tryggvasson / Stockholm, Sweden
Judith S. Bond / Hershey, USA
+Bonnie F. Sloane / Detroit, USA
Gillian Murphy / Norwich, England
Carlos Lopez-Otin / Oviedo, Spain
David J. Loskutoff / La Jolla, USA

Proteases in Non-Neoplastic Processes
*Henning Birkedal-Hansen / Bethesda, USA
Christopher W. B. Peters / Freiburg, Germany
Peter Carmeite / Leuven, Belgium
Anne-Marie Mingers / Würzburg, Germany
Michael S. Pepper / Geneva, Switzerland
Carl-Erik H. Dempfle / Mannheim, Germany

Proteases in Cell Growth and Death
*Peter A. Andreasen / Aarhus, Denmark
Guy S. Salvesen / San Diego, USA
Joan V. Ruderman / Boston, USA
Daniel B. Rifkin / New York, USA
Marcel Garcia / Montpellier, France
Francesco Blasi / Milano, Italy

Proteases in Tumor Progression I
*Jørgen Rygaard / Copenhagen, Denmark
Lynn M. Matrisian / Nashville, USA
+Yves A. De Clerck / Los Angeles, USA
Thomas H. Bugge / Cincinnati, USA
Keld Danø / Copenhagen, Denmark

Proteases in Tumor Progression II
*Henri Rochefort / Montpellier, France
Mina J. Bissell / Berkeley, USA
Paul Basset / Illkirch, France
Motoharu Seiki / Tokyo, Japan
+William G. Stetler-Stevenson / Bethesda, USA

Prognostic and Therapeutic Applications
*Antti I. Vaheri / Helsinki, Finland
John A. Foekens / Rotterdam, The Netherlands
+Nils Brünner / Copenhagen, Denmark
Steven Rosenberg / Emeryville, USA
Peter D. Brown / Oxford, England

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: April 3, 1998

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483 USA
215-440-9300 215-440-9313 (FAX)
e-mail: meetings@aacr.org
AACR Website: http://www.aacr.org

* Indicates Member of the Organizing Committee
+ Indicates Session Chairperson

Additional speakers to be announced.
Hit our Home Page on the World Wide Web!

http://www.aacr.org

Our web site features . . .

- **AACR scientific meeting schedule**
- **Table of Contents of AACR journals**
- **Instructions for Authors**
- **Information about AACR Research Fellowships and Travel Awards**

*Plus . . . The latest AACR newsletter, and much more!*
Edward Ziff's (cover)* research interests have moved progressively from the chemical to the biological over the 30 years of his career. However, throughout all that time, he has been concerned with informational macromolecules and their contributions to signal transduction. For his thesis with J. Fresco in Princeton in 1969, he devised original spectroscopic methods for observing conformational changes in transfer RNA molecules. In 1970, he moved to the MRC Laboratory of Molecular Biology in Cambridge, England, for his postdoctoral work, where in the laboratory of Fred Sanger, with J. Sedat and F. Galibert, he helped to devise the first methods for direct DNA sequencing and completed the first DNA sequence, that of a fragment of ΦX174 DNA (Nat. New Biol., 241: 34, 1973). His interests in DNA structure led him, in 1973, to the Imperial Cancer Research Fund Laboratories in London to study the DNA tumor viruses, whose small genomes contained the eukaryotic genes which were the most approachable at that time. The abilities of polyoma and SV40 to transform cells drew Dr. Ziff's interests toward the relationship among eukaryotic transcription, cellular transformation, and growth control. In 1975, he joined the faculty of Rockefeller University, where he studied the transcription of Adenovirus-2 genes in J. Darnell's Department of Molecular Cell Biology. There, he and R. Evans defined the first structure of an RNA polymerase II promoter (Cell, 15: 1463, 1978), the Ad-2 major late promoter, and later with C. Baker, he structurally mapped all of the early and delayed early promoters of the Ad-2 genome. With N. Fraser, Dr. Ziff also revealed the presence of multiple poly A sites within the Ad-2 major late transcription unit and the overlapping nature of the late messenger RNA species of Ad-2.

In 1981, Dr. Ziff joined the New York University Medical Center, where he turned his attention to cell growth control studies. Initially, he analyzed the Ad-2 Ela protein, a viral transformation protein, and with R. Stein and A. Velcich demonstrated several novel properties of this protein including Ela's ability to induce transportation of specific cellular genes and to repress transcription dependent upon enhancer elements. The fact that a viral oncoprotein, Ela, could regulate cellular promoters during growth induction led Dr. Ziff to search for the comparable cellular mechanisms which control transcription during growth. His quest for genes induced by growth factors led to the discovery with M. Greenberg of the serum induction of the c-fos immediate early gene (Nature, 311: 433, 1984). The c-fos studies revealed the first outlines of what is now known to be the Ras-MAP kinase pathway, by which receptor tyrosine kinases activate immediate early genes, including c-fos. In parallel with these studies, Dr. Ziff investigated the structural and functional properties of the early response protein transcription factors themselves, including c-Fos and c-Myc, and of C/EBP-α and -β, which are c-fos gene regulators. With T. Kouzarides, he elucidated the role of the c-Fos leucine zipper in the Fos-Jun interaction (Nature, 336: 646, 1988), and in work with G. Prendergast, Dr. Ziff's lab became one of two to clone the c-Myc partner, Max (Cell, 65: 395, 1991).

In 1990, Dr. Ziff was appointed Investigator of the Howard Hughes Medical Institute. In his subsequent research, Dr. Ziff began to focus on neural cells. In a collaboration with L. Greene, he investigated a gene program induced by nerve growth factor (NGF) in PC12 cells. He defined different kinetic classes of genes induced by NGF and placed the NGF controlled genes in a biological context. With E. Gizang-Ginsberg, Dr. Ziff showed that the immediate early c-fos gene induced the delayed early tyrosine hydroxylase gene, providing activity-dependent regulation of the catecholamine synthesis pathway. Dr. Ziff also identified genes controlled by NGF during the arrest of growth and the differentiation of PC12. These genes, studied in Dr. Ziff's lab by J. Gorham, K. Buchkovich, and G. Yan, are late genes which encode structural components of PC12 neurites or components of the cell cycle machinery such as the cell cycle kinase inhibitor, p21, and the cyclins and cdk kinases. Their control helps to explain the induction of differentiation and arrest of PC12 growth by NGF.

Dr. Ziff has also examined the contributions of Myc to cell transformation. With L. Li, he revealed a novel capacity of Myc to repress transcription of genes which are expressed exclusively in the differentiated state or which encode growth arrest functions (EMBO J., 13: 4070, 1994).

Recently, Dr. Ziff has extended his interests to signaling in mature neurons and has focused on the roles of glutamate receptors in activity-dependent changes in neuron phenotype. This work promises to divulge how synaptic strength can be regulated at the molecular level and how such changes can be translated into functional changes in the neuron through the expression of specific genes.

Throughout his career, Dr. Ziff has sought to illuminate molecular mechanisms of information transfer in cells and to relate these mechanisms to biological properties of cells and to problems of disease, cancer in particular. He has served on a number of advisory panels, including the Council of the American Cancer Society and the Israel Cancer Research Fund International Scientific Advisory Board, and he has been Chairman of a NCI-Frederick Cancer Research and Development Center Advisory Committee.

* Photo by Susan Taylorson.

Sidney Weinhouse